Investigating T cell ratios in patients with IgA nephropathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study examines the ratio of follicular helper T cells to regulatory follicular helper T cells in patients diagnosed with IgA nephropathy. It aims to differentiate between stable and progressive forms of the disease by analyzing blood and urine samples. The study will also seek to predict the clinical evolution of the disease within the first year of diagnosis. Participants will include patients with confirmed IgA nephropathy and control patients with other kidney conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* IgA nephropathy histologically proven on renal biopsy according to KDIGO criteria, with 8 permeable glomeruli (patients diagnosed from 2009 with a minimum follow-up for their nephropathy of 5 years (arm 1) or patients diagnosed during the study (arm 2))

Control patients: Lupus or ANCA-associated vasculitis or polycystic kidney disease (arm 3)

Exclusion Criteria:

* Legal incapacity or limited legal capacity
* Subjects with no social security coverage.
* Pregnancy / No effective contraceptive method

Where it's running

• Centre Hospitalier Universitaire de Besançon
  Besançon, France Recruiting

Study contacts

• Principal investigator: Melchior Chabannes, MD — Nephrology, CHU Besançon
• Study coordinator: Charline Vauchy, PhD.
• Email: cvauchy@chu-besancon.fr
• Phone: 0381218875

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term zigakibart treatment for adults with IgA nephropathy

  Adults with IgA nephropathy who finished an earlier zigakibart trial will receive ongoing subcutaneous zigakibart every two weeks to see if it stays safe and helps over the long term.

  Recruiting at 26 sites Phase 3 Novartis · Denver, Colorado and 25 other locations · NCT06858319

• Iptacopan added to standard care to change kidney biopsy findings in adults with IgA nephropathy

  This will try iptacopan added to standard treatment for adults with biopsy-confirmed IgA nephropathy to see if it reduces mesangial complement (C3c) deposits and improves kidney biomarkers over 9 months.

  Recruiting at 19 sites Phase 2 Novartis · Birmingham, Alabama and 18 other locations · NCT06797518

• Evaluating immunosuppressive therapy for IgA nephropathy in patients with advanced chronic kidney disease

  This study is testing if a combination of low-dose steroids and another medication can help people with IgA nephropathy and advanced kidney disease feel better and manage their symptoms.

  Recruiting Phase 3 Air Force Military Medical University, China · Xi'an · NCT05510323

• Sparsentan for IgA Nephropathy: safety and activity in adults with incident IgAN and recurrent IgAN after transplant

  This trial tests whether sparsentan can be safely given and help kidney outcomes in adults with immunoglobulin A nephropathy, including people newly diagnosed who haven’t had ACEI/ARB therapy and people with recurrent IgAN after kidney transplant.

  Recruiting at 6 sites Phase 2 University of Leicester · Cambridge, England and 5 other locations · NCT04663204

• Data repository for kidney diseases and related conditions

  This study is collecting health information and samples from people with different kidney diseases to see how various factors affect their condition and treatment.

  Recruiting The Rogosin Institute · New York, New York · NCT01802034

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.